Systemic-onset juvenile idiopathic arthritis: Difference between revisions
From WikiMD's Wellness Encyclopedia
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{Infobox medical condition | |||
| name = Systemic-onset juvenile idiopathic arthritis | |||
| synonyms = Still's disease, systemic juvenile idiopathic arthritis | |||
| field = [[Rheumatology]] | |||
| symptoms = [[Fever]], [[rash]], [[arthritis]], [[lymphadenopathy]], [[hepatosplenomegaly]] | |||
| complications = [[Macrophage activation syndrome]], [[growth retardation]] | |||
| onset = Childhood | |||
| duration = Chronic | |||
| causes = Unknown | |||
| risks = Genetic predisposition | |||
| diagnosis = Clinical evaluation, [[blood test]]s | |||
| differential = [[Infection]], [[malignancy]], other forms of [[juvenile idiopathic arthritis]] | |||
| treatment = [[Nonsteroidal anti-inflammatory drug]]s, [[corticosteroid]]s, [[disease-modifying antirheumatic drug]]s, [[biologic therapy]] | |||
| medication = [[Methotrexate]], [[etanercept]], [[anakinra]], [[tocilizumab]] | |||
| prognosis = Variable; can be severe | |||
| frequency = Rare | |||
}} | |||
{{Short description|A subtype of juvenile idiopathic arthritis characterized by systemic symptoms}} | {{Short description|A subtype of juvenile idiopathic arthritis characterized by systemic symptoms}} | ||
'''Systemic-onset juvenile idiopathic arthritis''' (SoJIA) is a subtype of [[juvenile idiopathic arthritis]] (JIA) that is distinguished by its systemic features, including fever, rash, and inflammation of internal organs, in addition to arthritis. It is a rare and complex condition that primarily affects children. | '''Systemic-onset juvenile idiopathic arthritis''' (SoJIA) is a subtype of [[juvenile idiopathic arthritis]] (JIA) that is distinguished by its systemic features, including fever, rash, and inflammation of internal organs, in addition to arthritis. It is a rare and complex condition that primarily affects children. | ||
==Clinical Features== | ==Clinical Features== | ||
Systemic-onset juvenile idiopathic arthritis is characterized by a combination of systemic and articular symptoms. The hallmark features include: | Systemic-onset juvenile idiopathic arthritis is characterized by a combination of systemic and articular symptoms. The hallmark features include: | ||
* '''Fever''': Patients typically experience a daily fever that spikes once or twice a day, often reaching 39°C (102°F) or higher. | |||
* '''Fever''': Patients typically experience a daily fever that spikes once or twice a day, often reaching | |||
* '''Rash''': A transient, salmon-colored rash may appear, often coinciding with fever spikes. The rash is usually non-itchy and can appear on the trunk and extremities. | * '''Rash''': A transient, salmon-colored rash may appear, often coinciding with fever spikes. The rash is usually non-itchy and can appear on the trunk and extremities. | ||
* '''Arthritis''': Joint inflammation is a key feature, affecting one or more joints. The arthritis can be persistent and may lead to joint damage if not adequately treated. | * '''Arthritis''': Joint inflammation is a key feature, affecting one or more joints. The arthritis can be persistent and may lead to joint damage if not adequately treated. | ||
| Line 12: | Line 27: | ||
* '''Hepatosplenomegaly''': Enlargement of the liver and spleen may occur. | * '''Hepatosplenomegaly''': Enlargement of the liver and spleen may occur. | ||
* '''Serositis''': Inflammation of serous membranes, such as the pleura or pericardium, can lead to pleuritis or pericarditis. | * '''Serositis''': Inflammation of serous membranes, such as the pleura or pericardium, can lead to pleuritis or pericarditis. | ||
==Pathophysiology== | ==Pathophysiology== | ||
The exact cause of systemic-onset juvenile idiopathic arthritis is unknown, but it is believed to involve a combination of genetic and environmental factors. The condition is thought to be an autoinflammatory disease, characterized by dysregulation of the innate immune system. Key cytokines involved in the inflammatory process include [[interleukin-1]] (IL-1), [[interleukin-6]] (IL-6), and [[interleukin-18]] (IL-18). | The exact cause of systemic-onset juvenile idiopathic arthritis is unknown, but it is believed to involve a combination of genetic and environmental factors. The condition is thought to be an autoinflammatory disease, characterized by dysregulation of the innate immune system. Key cytokines involved in the inflammatory process include [[interleukin-1]] (IL-1), [[interleukin-6]] (IL-6), and [[interleukin-18]] (IL-18). | ||
==Diagnosis== | ==Diagnosis== | ||
Diagnosis of SoJIA is primarily clinical, based on the characteristic symptoms and exclusion of other conditions. Laboratory tests may show elevated inflammatory markers such as [[C-reactive protein]] (CRP) and [[erythrocyte sedimentation rate]] (ESR). Other tests may include: | Diagnosis of SoJIA is primarily clinical, based on the characteristic symptoms and exclusion of other conditions. Laboratory tests may show elevated inflammatory markers such as [[C-reactive protein]] (CRP) and [[erythrocyte sedimentation rate]] (ESR). Other tests may include: | ||
* '''Complete blood count (CBC)''': May show anemia, leukocytosis, and thrombocytosis. | * '''Complete blood count (CBC)''': May show anemia, leukocytosis, and thrombocytosis. | ||
* '''Ferritin levels''': Often elevated in SoJIA. | * '''Ferritin levels''': Often elevated in SoJIA. | ||
* '''Antinuclear antibody (ANA) and rheumatoid factor (RF)''': Typically negative in SoJIA. | * '''Antinuclear antibody (ANA) and rheumatoid factor (RF)''': Typically negative in SoJIA. | ||
==Treatment== | ==Treatment== | ||
The management of systemic-onset juvenile idiopathic arthritis involves controlling inflammation and preventing joint damage. Treatment options include: | The management of systemic-onset juvenile idiopathic arthritis involves controlling inflammation and preventing joint damage. Treatment options include: | ||
* '''Nonsteroidal anti-inflammatory drugs (NSAIDs)''': Used to reduce pain and inflammation. | * '''Nonsteroidal anti-inflammatory drugs (NSAIDs)''': Used to reduce pain and inflammation. | ||
* '''Corticosteroids''': May be used for rapid control of severe systemic symptoms. | * '''Corticosteroids''': May be used for rapid control of severe systemic symptoms. | ||
* '''Disease-modifying antirheumatic drugs (DMARDs)''': Such as [[methotrexate]], may be used for long-term management. | * '''Disease-modifying antirheumatic drugs (DMARDs)''': Such as [[methotrexate]], may be used for long-term management. | ||
* '''Biologic agents''': Targeted therapies such as [[IL-1 inhibitors]] (e.g., anakinra) and [[IL-6 inhibitors]] (e.g., tocilizumab) have shown efficacy in treating SoJIA. | * '''Biologic agents''': Targeted therapies such as [[IL-1 inhibitors]] (e.g., anakinra) and [[IL-6 inhibitors]] (e.g., tocilizumab) have shown efficacy in treating SoJIA. | ||
==Prognosis== | ==Prognosis== | ||
The prognosis of systemic-onset juvenile idiopathic arthritis varies. Some children experience a monophasic course with complete resolution, while others may have a chronic or polycyclic course with persistent arthritis and systemic symptoms. Early and aggressive treatment can improve outcomes and reduce the risk of complications. | The prognosis of systemic-onset juvenile idiopathic arthritis varies. Some children experience a monophasic course with complete resolution, while others may have a chronic or polycyclic course with persistent arthritis and systemic symptoms. Early and aggressive treatment can improve outcomes and reduce the risk of complications. | ||
==Related Pages== | ==Related Pages== | ||
* [[Juvenile idiopathic arthritis]] | * [[Juvenile idiopathic arthritis]] | ||
| Line 39: | Line 47: | ||
* [[Interleukin-1]] | * [[Interleukin-1]] | ||
* [[Interleukin-6]] | * [[Interleukin-6]] | ||
[[Category:Juvenile arthritis]] | [[Category:Juvenile arthritis]] | ||
[[Category:Rheumatology]] | [[Category:Rheumatology]] | ||
[[Category:Pediatrics]] | [[Category:Pediatrics]] | ||
Latest revision as of 02:12, 4 April 2025
| Systemic-onset juvenile idiopathic arthritis | |
|---|---|
| Synonyms | Still's disease, systemic juvenile idiopathic arthritis |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Fever, rash, arthritis, lymphadenopathy, hepatosplenomegaly |
| Complications | Macrophage activation syndrome, growth retardation |
| Onset | Childhood |
| Duration | Chronic |
| Types | N/A |
| Causes | Unknown |
| Risks | Genetic predisposition |
| Diagnosis | Clinical evaluation, blood tests |
| Differential diagnosis | Infection, malignancy, other forms of juvenile idiopathic arthritis |
| Prevention | N/A |
| Treatment | Nonsteroidal anti-inflammatory drugs, corticosteroids, disease-modifying antirheumatic drugs, biologic therapy |
| Medication | Methotrexate, etanercept, anakinra, tocilizumab |
| Prognosis | Variable; can be severe |
| Frequency | Rare |
| Deaths | N/A |
A subtype of juvenile idiopathic arthritis characterized by systemic symptoms
Systemic-onset juvenile idiopathic arthritis (SoJIA) is a subtype of juvenile idiopathic arthritis (JIA) that is distinguished by its systemic features, including fever, rash, and inflammation of internal organs, in addition to arthritis. It is a rare and complex condition that primarily affects children.
Clinical Features[edit]
Systemic-onset juvenile idiopathic arthritis is characterized by a combination of systemic and articular symptoms. The hallmark features include:
- Fever: Patients typically experience a daily fever that spikes once or twice a day, often reaching 39°C (102°F) or higher.
- Rash: A transient, salmon-colored rash may appear, often coinciding with fever spikes. The rash is usually non-itchy and can appear on the trunk and extremities.
- Arthritis: Joint inflammation is a key feature, affecting one or more joints. The arthritis can be persistent and may lead to joint damage if not adequately treated.
- Lymphadenopathy: Swollen lymph nodes are common.
- Hepatosplenomegaly: Enlargement of the liver and spleen may occur.
- Serositis: Inflammation of serous membranes, such as the pleura or pericardium, can lead to pleuritis or pericarditis.
Pathophysiology[edit]
The exact cause of systemic-onset juvenile idiopathic arthritis is unknown, but it is believed to involve a combination of genetic and environmental factors. The condition is thought to be an autoinflammatory disease, characterized by dysregulation of the innate immune system. Key cytokines involved in the inflammatory process include interleukin-1 (IL-1), interleukin-6 (IL-6), and interleukin-18 (IL-18).
Diagnosis[edit]
Diagnosis of SoJIA is primarily clinical, based on the characteristic symptoms and exclusion of other conditions. Laboratory tests may show elevated inflammatory markers such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Other tests may include:
- Complete blood count (CBC): May show anemia, leukocytosis, and thrombocytosis.
- Ferritin levels: Often elevated in SoJIA.
- Antinuclear antibody (ANA) and rheumatoid factor (RF): Typically negative in SoJIA.
Treatment[edit]
The management of systemic-onset juvenile idiopathic arthritis involves controlling inflammation and preventing joint damage. Treatment options include:
- Nonsteroidal anti-inflammatory drugs (NSAIDs): Used to reduce pain and inflammation.
- Corticosteroids: May be used for rapid control of severe systemic symptoms.
- Disease-modifying antirheumatic drugs (DMARDs): Such as methotrexate, may be used for long-term management.
- Biologic agents: Targeted therapies such as IL-1 inhibitors (e.g., anakinra) and IL-6 inhibitors (e.g., tocilizumab) have shown efficacy in treating SoJIA.
Prognosis[edit]
The prognosis of systemic-onset juvenile idiopathic arthritis varies. Some children experience a monophasic course with complete resolution, while others may have a chronic or polycyclic course with persistent arthritis and systemic symptoms. Early and aggressive treatment can improve outcomes and reduce the risk of complications.
